Is granix a biosimilar?

Is Granix (tbo-something) considered a biosimilar?

Granix is not described as a biosimilar in the information provided. It is a brand of tbo-filgrastim, a medication used to help reduce the risk of infection from low white blood cell counts.

What it is instead: a “follow-on” filgrastim product

Granix is a follow-on biologic/biologic product based on filgrastim (a granulocyte-colony stimulating factor). Depending on the country and regulatory pathway, these products may be treated differently than true “biosimilars” under the law, but based on the provided context, Granix is not labeled as a biosimilar.

How to confirm for your situation

If you’re checking for switching or insurance purposes, the most direct way is to look at the drug’s label/regulatory designation in your country (for example, the “biosimilar” wording in the prescribing information or national drug registry). If you share your country, I can tailor the wording to how approvals are described there.